Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study
Guselkumab and risankizumab have the most favourable drug survival for effectiveness, with comparable safety to ustekinumab, and more favourable than other BADBIR biologics. Longer drug survival may reduce treatment burden by minimizing treatment switches, clinic visits and disease flares, supporting IL-23p19 inhibitors as a practical long-term option for psoriasis.
Authors
- Philip Hampton (ORCID: https://orcid.org/0000-0001-6797-2697)
- Zenas Z N Yiu (ORCID: https://orcid.org/0000-0002-1831-074X)
- Oras Alabas (ORCID: https://orcid.org/0000-0003-2002-0781)
- Nick J. Reynolds (ORCID: https://orcid.org/0000-0002-6484-825X)
- Christopher E.M. Griffiths (ORCID: https://orcid.org/0000-0001-5371-4427)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Catherine Smith (ORCID: https://orcid.org/0000-0001-9918-1144)
- Leila Motedayen Aval (ORCID: https://orcid.org/0009-0005-7352-6454)
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Manchester Academic Health Science Centre (GB)
- Royal Victoria Infirmary (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University of Manchester (GB)
- Salford Royal Hospital (GB)
- NIHR Newcastle Biomedical Research Centre (GB)
- King's College Hospital (GB)
- Newcastle University (GB)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1111/jdv.20739
- Citations
- 14
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 11.16